Sicagen India

Why is Sicagen India Ltd falling/rising?

As of 06-Aug, Sicagen India Ltd's stock price is rising to Rs 61.79, reflecting a 19.93% increase. This rise is driven by strong buying interest, significant outperformance against the Sensex, and increased investor participation, indicating a bullish sentiment.

As of 06-Aug, Sicagen India Ltd's stock price is rising, currently at Rs 61.79, reflecting a change of Rs 10.27 or 19.93% increase. This upward movement is supported by several factors. Over the past week, the stock has gained 26.59%, significantly outperforming the Sensex, which only increased by 1.32% during the same period. Additionally, the stock has shown a remarkable performance over the last two days, with a return of 23.58%. <BR><BR>Today, the stock reached an intraday high of Rs 61.82, indicating strong buying interest. The trading activity has been characterized by high volatility, with an intraday volatility of 6.04%. Furthermore, Sicagen India Ltd is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals positive momentum. <BR><BR>Investor participation has also increased, with delivery volume rising by 104.25% compared to the 5-day average, suggesting heightened interest from investors. Overall, these factors contribute to the stock's rising price, indicating a strong bullish sentiment among investors.

Which are the latest news on Sicagen India?

When is the next results date for Sicagen India Ltd?

The next results date for Sicagen India Ltd is 10 August 2026.

The next results date for Sicagen India Ltd is scheduled for 10 August 2026.

How big is Sicagen India?

As of 10th June, Sicagen India Ltd has a market capitalization of 212.00 Cr, with recent net sales of 973.48 Cr and a net profit of 18.07 Cr. The company reported shareholder's funds of 483.99 Cr and total assets of 721.69 Cr for the annual period ending March 2025.

As of 10th June, Sicagen India Ltd has a market capitalization of 212.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sicagen India reported Net Sales of 973.48 Cr and a Net Profit of 18.07 Cr.<BR><BR>For the latest annual period ending March 2025, the company had Shareholder's Funds of 483.99 Cr and Total Assets amounting to 721.69 Cr.

Who are in the management team of Sicagen India?

The management team of Sicagen India includes B Narendran, Ashwin C Muthiah (Chairman), Sashikala Srikanth, Rita Chandrasekar, S Radhakrishnan, R Chandrasekar, M Rajamani, S R Ramakrishnan, Varma Nandakumar, and Ankita Jain (Company Secretary). This team offers a diverse range of expertise and leadership.

The management team of Sicagen India includes the following individuals:<BR><BR>1. **B Narendran** - Independent Director<BR>2. **Ashwin C Muthiah** - Chairman (Non-Executive)<BR>3. **Sashikala Srikanth** - Independent Director<BR>4. **Rita Chandrasekar** - Independent Director<BR>5. **S Radhakrishnan** - Independent Director<BR>6. **R Chandrasekar** - Director<BR>7. **M Rajamani** - Independent Director<BR>8. **S R Ramakrishnan** - Director<BR>9. **Varma Nandakumar** - Additional Director<BR>10. **Ankita Jain** - Company Secretary & Compliance Officer<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Sicagen India?

Sicagen India's peers include Sakuma Exports, Vikas Lifecare, and Chandrima Mercan, among others. Management risk varies from excellent to below average, with growth ratings similarly diverse, while Sakuma Exports has the highest 1-year return at -45.09%.

Peers: The peers of Sicagen India are Sakuma Exports, Vikas Lifecare, Chandrima Mercan, Northern Spirits, Stratmont Indus., Parshva Enterpr., Astal Lab, and Chemkart India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Chandrima Mercan and Chemkart India, while Average management risk is found at Sakuma Exports, Northern Spirits, Stratmont Indus., and Astal Lab, and the rest have Below Average management risk. Growth is Excellent at Chandrima Mercan and Astal Lab, Good at Sicagen India, and the rest have Below Average growth except for Northern Spirits and Stratmont Indus., which have Excellent growth. Capital Structure is Excellent at Chemkart India and Chandrima Mercan, Good at Sakuma Exports and Parshva Enterpr., while Sicagen India and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sakuma Exports at -45.09%, while Vikas Lifecare has the lowest at -45.49%, with Sicagen India's 1-year return being not available for comparison. Additionally, peers such as Sakuma Exports and Vikas Lifecare have negative six-month returns.

What does Sicagen India do?

Sicagen India Ltd is a micro-cap company specializing in trading and marketing services for construction-related infrastructure. As of March 2026, it reported net sales of ₹278 crore and a net profit of ₹4 crore.

Overview:<BR>Sicagen India Ltd is a leading provider of trading and marketing services for construction-related industrial and retail infrastructure, operating in the Trading & Distributors industry within the Micro Cap market.<BR><BR>History:<BR>Sicagen India Ltd was incorporated on June 11, 2004. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 278 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 212 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 12.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 1.84% <BR>Debt-Equity: 0.15 <BR>Return on Equity: 3.70% <BR>Price to Book: 0.43 <BR><BR>Contact Details:<BR>Address: 4th Floor SPIC House, No 88 Mount Road Guindy Chennai Tamil Nadu : 600032 <BR>Tel: 91-044-4075 4075 <BR>Email: secl@sicagen.com <BR>Website: http://www.sicagen.com

Are Sicagen India Ltd latest results good or bad?

Sicagen India Ltd's latest results show strong revenue growth with a record ₹277.91 crores in Q4 FY26, but net profit declined 9.53% quarter-on-quarter due to rising interest expenses, raising concerns about profitability sustainability. Investors should be cautious given these mixed signals.

Sicagen India Ltd's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly revenue of ₹277.91 crores in Q4 FY26, reflecting a solid year-on-year growth of 10.49% and a sequential increase of 5.16%. This demonstrates healthy demand across its diversified business segments.<BR><BR>However, the net profit for the same quarter was ₹4.46 crores, which is a decline of 9.53% compared to the previous quarter, although it shows a positive year-on-year increase of 12.34%. This sequential profit drop raises concerns about the sustainability of profitability, especially given that interest expenses surged by 60% quarter-on-quarter, significantly impacting the company's margins.<BR><BR>The operating margin stood at 4.04%, which, while improving from the previous quarter, still reflects a slight year-on-year decline. The PAT margin also contracted to 1.60%, indicating pressure on profitability.<BR><BR>Overall, while the revenue growth is a positive sign, the declining net profit and rising interest costs suggest that the company faces significant operational challenges. Investors should be cautious and consider these factors when evaluating the overall performance of Sicagen India Ltd.

Should I buy, sell or hold Sicagen India Ltd?

How has been the historical performance of Sicagen India?

Sicagen India's historical performance shows fluctuating net sales and profits, peaking at 895.30 Cr in March 2023 before declining slightly to 891.88 Cr in March 2025. Despite this, operating profit and profit before tax improved, indicating enhanced operational efficiency and a stable financial position.

Answer:<BR>The historical performance of Sicagen India shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Sicagen India's net sales peaked at 895.30 Cr in March 2023 but saw a slight decline to 891.88 Cr in March 2025. The total operating income followed a similar pattern, reaching 895.30 Cr in March 2023 and then decreasing to 891.88 Cr in March 2025. The company's total expenditure, excluding depreciation, was 856.38 Cr in March 2025, up from 768.29 Cr in March 2024. Operating profit (PBDIT) increased to 43.56 Cr in March 2025 from 34.26 Cr in March 2024, indicating improved operational efficiency. Profit before tax also rose to 24.18 Cr in March 2025, compared to 13.84 Cr in March 2024, while profit after tax was 17.11 Cr in March 2025, slightly down from 17.82 Cr in March 2023. The company's total assets were 721.69 Cr in March 2025, with total liabilities at 721.69 Cr, reflecting a stable financial position. Cash flow from operating activities improved to 33.00 Cr in March 2025, up from 24.00 Cr in March 2024, contributing to a net cash inflow of 1.00 Cr in March 2025. Overall, Sicagen India has shown resilience with a gradual recovery in profits and cash flow despite fluctuations in sales.

Is Sicagen India overvalued or undervalued?

As of October 24, 2024, Sicagen India is considered very attractive with a PE ratio of 17.29, a Price to Book Value of 0.55, and an EV to EBITDA of 9.79, significantly outperforming its peers and the Sensex, indicating it is undervalued in the market.

As of 24 October 2024, Sicagen India has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 17.29, a Price to Book Value of 0.55, and an EV to EBITDA of 9.79. In comparison to its peers, Sicagen's PEG ratio stands at a notably low 0.37, while MMTC, a peer, has a significantly high PE ratio of 119.39, indicating that Sicagen is positioned favorably within its industry.<BR><BR>The company's recent performance has also been noteworthy, with a one-month stock return of 24.97%, significantly outperforming the Sensex's 3.88% return over the same period. This performance, combined with its attractive valuation metrics, reinforces the conclusion that Sicagen India is undervalued relative to its peers and the broader market.

What is the technical trend for Sicagen India?

As of May 12, 2025, Sicagen India shows a mildly bearish trend overall, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, despite some mildly bullish indicators on the weekly chart.

As of 12 May 2025, the technical trend for Sicagen India has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish. The Bollinger Bands show a bullish signal on the weekly chart but are mildly bearish on the monthly. The daily moving averages are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly but mildly bearish on the monthly, and Dow Theory supports a mildly bullish outlook on both time frames. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the MACD and Bollinger Bands.

Who are the top shareholders of the Sicagen India?

The top shareholders of Sicagen India include Ranford Investments Ltd. with 18.7%, followed by individual investors at 28.37%, and Mercantile Ventures Limited at 2.5%. There is also one Foreign Institutional Investor holding 2.42%, while mutual funds have minimal involvement.

The top shareholders of Sicagen India include several key players. The majority shareholders are the promoters, with no pledged promoter holdings reported. The promoter with the highest holding is Ranford Investments Ltd., which holds 18.7% of the shares. <BR><BR>In terms of institutional investors, there is one Foreign Institutional Investor (FII) that holds 2.42% of the company. Additionally, mutual funds have a minimal presence, with three schemes holding 0.0%. <BR><BR>Among public shareholders, Mercantile Ventures Limited is the largest, holding 2.5%. Individual investors collectively hold 28.37% of the shares.

Has Sicagen India declared dividend?

Yes, Sicagen India Ltd has declared a 6% dividend, amounting to 0.6 per share, with an ex-date of September 12, 2024. The company has shown varying total returns over different periods, with significant long-term price growth.

Sicagen India Ltd has declared a 6% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 6%<BR>- Amount per share: 0.6<BR>- Ex-date: 12 Sep 2024<BR><BR>Dividend Yield: 0.88%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Sicagen India experienced a price return of -25.03% with no dividend return, resulting in a total return of -25.03%.<BR><BR>Over the past year, the company had a price return of 14.83% and a dividend return of 1.02%, leading to a total return of 15.85%.<BR><BR>In the 2-year period, the price return was 44.4% with a dividend return of 2.72%, culminating in a total return of 47.12%.<BR><BR>For the 3-year period, Sicagen India saw a price return of 157.58% and a dividend return of 5.65%, which resulted in a total return of 163.23%.<BR><BR>In the last 4 years, the company achieved a price return of 195.65% along with a dividend return of 9.05%, leading to a total return of 204.7%.<BR><BR>Over the past 5 years, the price return was 352.13% with a dividend return of 18.91%, resulting in a total return of 371.04%.<BR><BR>Overall, Sicagen India has declared a dividend and demonstrated varying total returns across different periods, with significant growth in price returns over the longer term, indicating a positive trend in shareholder value.